Loading...
Indian Pharmaceutical Exporter · #8 for Etanercept · $3.9K export value · DGFT Verified
Rutva Medicare is the #8 Indian exporter of Etanercept with $3.9K in export value and 8 verified shipments. Rutva Medicare holds a 0.0% market share in Etanercept exports across 3 countries. The company exports 3 pharmaceutical products worth $9.7K across 3 therapeutic categories.
| SAUDI ARABIA | $200.0K | 4 | 2.7% |
| CANADA | $100.0K | 2 | 1.4% |
| PANAMA | $100.0K | 2 | 1.4% |
| UNITED KINGDOM | $54.9K | 45 | 0.7% |
| TAIWAN | $45.9K | 2 | 0.6% |
| CAYMAN ISLANDS | $35.5K | 3 | 0.5% |
India exports Etanercept to 29 countries. The top destination is JAPAN (38.6%), followed by POLAND and VENEZUELA.
| Buyer | Country | Value | Orders |
|---|---|---|---|
| NICHI-IKO PHARMACEUTICAL CO LTD | JAPAN | $1.4M | 27 |
| PRESPACK JACEK KARONSKI | POLAND | $950.0K | 19 |
| PRESPACK JACEK KARONSKI UL SADOWA | POLAND | $700.0K | 14 |
| PRESPACK SP Z.O.O | POLAND | $600.0K | 12 |
| NICHI-IKO PHARMACEUTICAL CO., LTD | JAPAN | $550.0K | 11 |
| NICHI-IKO PHARMACEUTICAL CO LIMITED | JAPAN | $550.0K | 11 |
| PRESPACK SP Z,O,O | POLAND | $300.0K | 6 |
| PSK PHARMA | RUSSIA | $200.0K | 4 |
| PSK PHARMA LIMITED | RUSSIA | $200.0K | 4 |
| PSK PHARMA., | RUSSIA | $100.0K | 2 |
India's Etanercept is purchased by 64 buyers worldwide. The top buyer is NICHI-IKO PHARMACEUTICAL CO LTD (JAPAN), followed by PRESPACK JACEK KARONSKI and PRESPACK JACEK KARONSKI UL SADOWA.
India exported $9.7M worth of Etanercept through 251 shipments from 27 suppliers to 29 countries, serving 64 buyers globally. Rutva Medicare contributes $3.9K to this total, accounting for 0.0% of India's Etanercept exports.
Rutva Medicare's average Etanercept shipment value is $485 per consignment, based on 8 shipments totaling $3.9K.
Rutva Medicare ranks #8 among 27 Indian Etanercept exporters with a 0.0% market share. The top 3 exporters are LUPIN LIMITED ($8.7M), RELIANCE LIFE SCIENCES PRIVATE LIMITED ($450.0K), AXA PARENTERALS LIMITED ($200.0K). Rutva Medicare processed 8 shipments to 3 destination countries.
What Rutva Medicare must comply with to export Etanercept to its top destination countries
Approval Process
Generic Drug Application per Japan Pharmaceutical Affairs Act. Dissolution and bioequivalence studies per PMDA guidelines. Japanese data bridging often required.
Timeline: 12–24 months
GMP & Export Requirements
Japanese GMP (J-GMP); PMDA on-site inspection of Indian manufacturing facility
Foreign Manufacturer Accreditation from PMDA; Japanese MAH (Marketing Authorization Holder) partner required
Note: Japan requires Yen-denominated NHI drug price listing. Stability data under ICH Zone IVb conditions.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
Exporters ranked immediately above and below #8 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 6 | ANR HEALTH CARE PRIVATE LIMITED | $32.7K | 10 | 1 | $3.3K |
| 7 | CITRO PHARMA PRIVATE LIMITED | $6.0K | 3 | 1 | $2.0K |
| 8 | RUTVA MEDICARE ★ | $3.9K | 8 | 3 | $485 |
| 9 | 3S PHARMACEUTICALS INDIA PRIVATE LIMITED | $1.2K | 3 | 1 | $396 |
Rutva Medicare ranks #8 among 27 Indian Etanercept exporters. Average shipment value of $485 compared to the market average of $359.3K. The closest competitors by value are ANR HEALTH CARE PRIVATE LIMITED and CITRO PHARMA PRIVATE LIMITED.
| Port | Shipments | % Share |
|---|---|---|
| SAHAR AIR | 95 | 37.8% |
| SAHAR AIR CARGO ACC (INBOM4) | 88 | 35.1% |
| Bombay Air | 22 | 8.8% |
| DELHI AIR | 13 | 5.2% |
| Bombay Air Cargo | 7 | 2.8% |
| DELHI AIR CARGO ACC (INDEL4) | 5 | 2.0% |
| BANGALORE ACC (INBLR4) | 4 | 1.6% |
| MUNDRA SEA (INMUN1) | 3 | 1.2% |
Rutva Medicare exports 3 products worth $9.7K. Beyond Etanercept, top products include Liraglutide, Ribavirin. View the complete Rutva Medicare profile for full portfolio analysis.
Latest developments and market context
Detailed market intelligence for Etanercept — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Verify manufacturer licensing and export certifications with the official agencies above.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 29+ countries, 64+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Rutva Medicare's Etanercept exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Rutva Medicare
Full Company Profile →
3 products · $9.7K total trade · 3 categories
Access shipment-level records, pricing trends, and buyer contacts for Rutva Medicare.
Request DemoView Pricing →Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Etanercept. For current shipment-level data, contact TransData Nexus.